WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016064078) COMPOSITION CONTAINING THYMOSIN BETA 4, AND PHARMACEUTICAL FORMULATION COMPRISING SAME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/064078    International Application No.:    PCT/KR2015/008621
Publication Date: 28.04.2016 International Filing Date: 18.08.2015
IPC:
A61K 38/04 (2006.01), A61K 9/08 (2006.01), A61K 47/02 (2006.01), A61K 38/16 (2006.01), A61K 38/17 (2006.01), A61P 27/02 (2006.01)
Applicants: G-TREEBNT CO., LTD. [KR/KR]; 22F, 248, Jeongjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13554 (KR)
Inventors: KANG, Sin Wook; (KR).
KIM, Kyoungsun; (KR).
LEE, Si Young; (KR).
SUNG, Ji Hye; (KR)
Agent: FIRSTLAW P.C.; 60 Mabang-Ro, Seocho-Ku Seoul 06775 (KR)
Priority Data:
10-2014-0143585 22.10.2014 KR
10-2014-0143606 22.10.2014 KR
Title (EN) COMPOSITION CONTAINING THYMOSIN BETA 4, AND PHARMACEUTICAL FORMULATION COMPRISING SAME
(FR) COMPOSITION CONTENANT DE LA THYMOSINE BÊTA 4 ET FORMULATION PHARMACEUTIQUE LA CONTENANT
(KO) 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
Abstract: front page image
(EN)The present invention relates to a therapeutic agent for ophthalmic disease, containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions, and is physiochemically safe.
(FR)La présente invention concerne un agent thérapeutique pour traiterdes maladies ophtalmiques, contenant de la thymosine bêta 4. La présente invention est plus efficace pour diminuer la xérophtalmie qu'une solution ophtalmique contenant de la cyclosporine A, est moins irritante pour les yeux que des solutions ophtalmiques classiques et est d'une utilisation fiable sur le plan physicochimique.
(KO)본 발명은 티모신 베타 4를 함유하는 안과질환치료제에 관한 것이다. 본 발명은 사이클로스포린 A 를 함유하는 점안액 보다 안구건조증 개선에 있어서 더 효과적이고, 종래의 점안액에 비해 눈에 대한 자극성이 덜하며, 물리 화학적으로 안정하다는 특징이 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)